查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1638796

2024 - 2032 年解剖病理学市场机会、成长驱动因素、产业趋势分析与预测

Anatomic Pathology Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年全球解剖病理学市场价值约为 367 亿美元，预计 2024 年至 2032 年复合年增长率为 7.8%。 。利用组织病理学、细胞病理学和尸检病理学等技术，解剖病理学家在细胞层面分析样本，揭示疾病过程引起的结构和功能变化。

疾病，特别是癌症的日益流行，推动了对解剖病理学服务的巨大需求。随着全球疾病负担的增加，对精确诊断工具的需求激增。组织病理学和细胞病理学等技术对于准确的疾病检测和管理、推动市场成长至关重要。此外，生物标记的广泛使用、病理设备的进步以及临床试验的增加都提高了诊断的准确性和可靠性。数位病理学等技术进一步支持诊断的效率和准确性，促进该行业的成长。

基于产品和服务的市场区隔包括仪器、消耗品和服务。消耗品领域在2023年创造了192亿美元的收入，引领市场，预计将保持强劲成长。精密玻片和试剂等高品质消耗品对于提高整个实验室的诊断准确性和标准化至关重要。即用型耗材使技术人员能够专注于样本分析，从而提高工作流程效率，最大限度地减少准备时间并提高实验室生产力。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 367 亿美元
预测值 719 亿美元
复合年增长率 7.8%

按应用划分，市场分为疾病诊断和研究，其中疾病诊断，特别是癌症诊断，将在2023 年占据相当大的市场份额。价值的见解，有助于准确诊断。与基因组学和蛋白​​质组学等分子测试技术的集成，透过将诊断结果与遗传和生物标记资料结合起来，进一步增强个人化医疗。

到 2023 年，医院的最终用途部分将占据 55.4% 的份额，并有望大幅成长。医院受益于广泛的诊断工具，可以采用全面的患者护理方法。先进的分子检测与解剖病理学相结合，使医院能够提供个人化治疗，尤其是肿瘤学治疗，从而提高治疗效果和患者满意度。

在北美，由于疾病盛行率高且完善的医疗基础设施，美国在解剖病理学市场中处于领先地位。包括数位病理学和人工智慧驱动工具在内的先进诊断技术已被广泛采用，提高了诊断准确性并改善了患者的整体护理。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 全球癌症和其他目标疾病的发生率不断上升
      • 越来越多地采用生物标誌物
      • 与癌症药物相关的临床试验数量不断增加
      • 病理设备技术不断进步
    • 产业陷阱与挑战
      • 设备成本高
      • 翻新解剖病理学系统的可用性
  • 成长潜力分析
  • 监管环境
  • 技术景观
    • 核心技术
    • 邻近技术
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品和服务划分，2021 - 2032 年

  • 主要趋势
  • 仪器仪表
    • 切片机
    • 细胞处理器
    • 组织处理系统
    • 玻片染色系统
    • 包埋系统
    • 盖玻片
    • 其他仪器
  • 耗材
    • 抗体
      • 一抗
      • 二抗
    • 试剂盒和试剂
      • 污渍和溶剂
      • 固定剂
      • 其他试剂盒和试剂
    • 探头
    • 其他消耗品
  • 服务
    • 组织病理学
    • 细胞病理学

第 6 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 疾病诊断
    • 癌症
      • 乳癌
      • 胃肠癌
      • 肺癌
      • 摄护腺癌
      • 其他癌症类型
    • 其他疾病
  • 研究

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院
  • 诊断中心
  • 其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 9 章：公司简介

  • Supply-side
  • Demand-side (Laboratories)
简介目录
Product Code: 12097

The Global Anatomic Pathology Market, valued at around USD 36.7 billion in 2023, is projected to grow at a CAGR of 7.8% from 2024 to 2032. Anatomic pathology, a specialized branch of pathology, focuses on diagnosing diseases by examining surgical specimens, tissues, and organs. Utilizing techniques like histopathology, cytopathology, and autopsy pathology, anatomic pathologists analyze samples at a cellular level, uncovering structural and functional changes caused by disease processes.

The growing prevalence of diseases, particularly cancer, drives significant demand for anatomic pathology services. With an increasing disease burden worldwide, the need for precise diagnostic tools has surged. Techniques like histopathology and cytopathology are critical for accurate disease detection and management, fueling market growth. Furthermore, the expanding use of biomarkers, advancements in pathology equipment, and the rise in clinical trials are all enhancing diagnostic precision and reliability. Technologies like digital pathology further support the efficiency and accuracy of diagnoses, contributing to the sector's growth.

Market segments based on products and services include instruments, consumables, and services. The consumables segment, which generated USD 19.2 billion in revenue in 2023, led the market and is anticipated to maintain robust growth. High-quality consumables, such as precision slides and reagents, are essential for improving diagnostic accuracy and standardization across labs. Ready-to-use consumables enhance workflow efficiency, minimizing preparation time and improving lab productivity by enabling technicians to focus on specimen analysis.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$36.7 Billion
Forecast Value$71.9 Billion
CAGR7.8%

By application, the market is divided into disease diagnostics and research, with disease diagnostics, particularly cancer diagnostics, holding a substantial market share in 2023. Anatomic pathology enables detailed tissue and cell analysis, providing valuable insights into disease morphology, which aids in accurate diagnosis. Integration with molecular testing techniques, like genomics and proteomics, further enhances personalized medicine by aligning diagnostic findings with genetic and biomarker data.

The end-use segment of hospitals held a 55.4% share in 2023 and is poised for substantial growth. Hospitals benefit from access to a broad range of diagnostic tools, allowing for a comprehensive approach to patient care. Advanced molecular testing, combined with anatomic pathology, enables hospitals to offer personalized treatments, especially for oncology, thus enhancing treatment outcomes and patient satisfaction.

In North America, the U.S. leads the anatomic pathology market due to high disease prevalence and a well-established healthcare infrastructure. Advanced diagnostic technologies, including digital pathology and AI-driven tools, are widely adopted, boosting diagnostic accuracy and enhancing overall patient care.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of cancer and other target diseases worldwide
      • 3.2.1.2 Growing adoption of biomarkers
      • 3.2.1.3 Increasing number of clinical trials pertaining to cancer drugs
      • 3.2.1.4 Increasing technological advancements of pathology equipment
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of equipment
      • 3.2.2.2 Availability of refurbished anatomic pathology systems
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product and Service, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments
    • 5.2.1 Microtomes
    • 5.2.2 Cell processors
    • 5.2.3 Tissue processing systems
    • 5.2.4 Slide staining systems
    • 5.2.5 Embedding systems
    • 5.2.6 Coverslippers
    • 5.2.7 Other instruments
  • 5.3 Consumables
    • 5.3.1 Antibodies
      • 5.3.1.1 Primary antibodies
      • 5.3.1.2 Secondary antibodies
    • 5.3.2 Kits and reagents
      • 5.3.2.1 Stains and solvents
      • 5.3.2.2 Fixatives
      • 5.3.2.3 Other kits and reagents
    • 5.3.3 Probes
    • 5.3.4 Other consumables
  • 5.4 Services
    • 5.4.1 Histopathology
    • 5.4.2 Cytopathology

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Diseases diagnostics
    • 6.2.1 Cancer
      • 6.2.1.1 Breast cancer
      • 6.2.1.2 Gastrointestinal cancer
      • 6.2.1.3 Lung cancer
      • 6.2.1.4 Prostate cancer
      • 6.2.1.5 Other cancer types
    • 6.2.2 Other diseases
  • 6.3 Research

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Diagnostic centers
  • 7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Supply-side
    • 9.1.1 Agilent Technologies
    • 9.1.2 Becton, Dickinson and Company
    • 9.1.3 Cardinal Health
    • 9.1.4 Danaher Corporation
    • 9.1.5 F. Hoffmann-La Roche
    • 9.1.6 Merck
    • 9.1.7 Thermo Fisher Scientific
  • 9.2 Demand-side (Laboratories)
    • 9.2.1 Ampath Laboratories
    • 9.2.2 Al Borg Medical Laboratories
    • 9.2.3 Biolab
    • 9.2.4 Eurofins Scientific
    • 9.2.5 Laboratoires Reunis
    • 9.2.6 Lifebrain Group
    • 9.2.7 Lancet Laboratories
    • 9.2.8 Medsol Diagnostics
    • 9.2.9 Synlab Group
    • 9.2.10 Unilabs